<p>雅培公司的股價在報告 2024 年第二季度業績後下跌，銷售額達到 103.77 億美元，每股收益為 1.14 美元，超出預期。儘管 COVID-19 測試銷售下降，但其他領域表現強勁，特別是在糖尿病護理、心臟電生理學和結構性心臟方面有增長。營養品銷售增長 3.5%，達到 21.5 億美元。然而，由於 COVID-19 測試收入下降，診斷銷售下降了 5.3%。公司獲得了各種醫療設備的 FDA 批准和 CE 標誌，並獲得了兩款連續葡萄糖監測系統的認可。雅培公司（ABT）報告了 2024 年第二季度的財務業績，展示了 4.0% 的銷售增長和基礎業務有機銷售增長 9.3% [1]。這一增長主要得益於醫療設備部門的兩位數增長。</p>
<p>儘管 COVID-19 測試銷售下降，雅培在其他領域表現強勁。糖尿病護理部門的銷售增長了 3.5%，達到 215 億美元 [1]。心臟電生理學和結構性心臟部門也表現出增長，雅培宣佈獲得了各種醫療設備的 FDA 批准和 CE 標誌 [1]。</p>
<p>然而，由於 COVID-19 測試收入下降，診斷部門經歷了 5.3% 的下滑 [1]。這一下滑被雅培在醫療設備部門持續取得的成功和新產品的批准所抵消。</p>
<p>今年 4 月，雅培獲得了 Esprit™ 膝下（BTK）系統的 FDA 批准，這是一項對患有周圍動脈疾病的人們具有突破性意義的創新 [1]。6 月，雅培獲得了兩款新的非處方連續葡萄糖監測系統 Lingo™和 Libre Rio™的 FDA 許可，並獲得了 AVEIR®雙腔（DR）無導聯起搏器系統的 CE 標誌 [1]。</p>
<p>雅培的研發管線也為公司的增長做出了貢獻，在 2024 年上半年宣佈了 10 個新的增長機會 [1]。這些機會包括新產品批准和新的治療適應症，進一步鞏固了雅培在醫療保健行業的領先地位。</p>
<p>參考資料：</p>
<p>[1] 雅培報告 2024 年第二季度業績並提高全年指引。 (2024, 7 月 18 日). 檢索自 https://abbott.mediaroom.com/2024-07-18-Abbott-Reports-Second-Quarter-2024-Results-and-Raises-Full-Year-Guidance</p>
<p><img src="https://imageproxy.pbkrs.com/https://lh-prod-oper-pub-opercenter.s3.amazonaws.com/discovery-image/compress-193039c16e8bc001.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://lh-prod-oper-pub-opercenter.s3.amazonaws.com/discovery-image/compress-193039c16e8bc001.png"/></p>

雅培

<p>儘管雅培（Abbott Laboratories）第二季度業績穩健，銷售額超出預期，但股價下跌。糖尿病護理、心臟電生理學和結構性心臟領域實現增長，而診斷銷售下降，原因是 COVID-19 測試收入減少。雅培獲得了 FDA 批准和 CE 標誌，用於各種醫療設備，並在醫療器械業績表現強勁。公司的研發管線通過新產品批准和治療適應症貢獻了增長</p>

<p>Abbott Laboratories' shares dropped after reporting Q2 2024 results, with sales at $10.377 billion and EPS at $1.14, exceeding expectations. Despite a decline in COVID-19 testing sales, other sectors showed growth, particularly in diabetes care, electrophysiology, and structural heart. Nutrition sales increased by 3.5% to $2.15 billion. However, diagnostics sales fell 5.3% due to the drop in COVID-19 testing revenue. The company received FDA approvals and CE Marks for various medical devices and cleared two continuous glucose monitoring systems.Abbott Laboratories (ABT) reported its second-quarter 2024 financial results, showcasing a sales growth of 4.0% and an organic sales growth for the underlying base business of 9.3% [1]. This growth was fueled primarily by double-digit growth in the Medical Devices segment.</p>
<div class="lb-trans"><p>雅培公司的股價在報告 2024 年第二季度業績後下跌，銷售額達到 103.77 億美元，每股收益為 1.14 美元，超出預期。儘管 COVID-19 測試銷售下降，但其他領域表現強勁，特別是在糖尿病護理、心臟電生理學和結構性心臟方面有增長。營養品銷售增長 3.5%，達到 21.5 億美元。然而，由於 COVID-19 測試收入下降，診斷銷售下降了 5.3%。公司獲得了各種醫療設備的 FDA 批准和 CE 標誌，並獲得了兩款連續葡萄糖監測系統的認可。雅培公司（ABT）報告了 2024 年第二季度的財務業績，展示了 4.0% 的銷售增長和基礎業務有機銷售增長 9.3% [1]。這一增長主要得益於醫療設備部門的兩位數增長。</p>
</div><p>Despite a decline in COVID-19 testing sales, Abbott's performance was buoyed by strong growth in other sectors. The Diabetes Care division experienced a 3.5% increase in sales to $2.15 billion [1]. The Electrophysiology and Structural Heart segments also showed growth, with Abbott announcing FDA approvals and CE Marks for various medical devices [1].</p>
<div class="lb-trans"><p>儘管 COVID-19 測試銷售下降，雅培在其他領域表現強勁。糖尿病護理部門的銷售增長了 3.5%，達到 215 億美元 [1]。心臟電生理學和結構性心臟部門也表現出增長，雅培宣佈獲得了各種醫療設備的 FDA 批准和 CE 標誌 [1]。</p>
</div><p>However, the Diagnostics segment experienced a 5.3% decline due to the drop in COVID-19 testing revenue [1]. This decline was offset by Abbott's continued success in the Medical Devices segment and the approval of new products.</p>
<div class="lb-trans"><p>然而，由於 COVID-19 測試收入下降，診斷部門經歷了 5.3% 的下滑 [1]。這一下滑被雅培在醫療設備部門持續取得的成功和新產品的批准所抵消。</p>
</div><p>In April, Abbott secured FDA approval for the Esprit™ below-the-knee (BTK) system, a groundbreaking innovation for people with peripheral artery disease [1]. In June, Abbott received FDA clearance for two new over-the-counter continuous glucose monitoring systems, Lingo™ and Libre Rio™, and obtained CE Mark for its AVEIR® dual chamber (DR) leadless pacemaker system [1].</p>
<div class="lb-trans"><p>今年 4 月，雅培獲得了 Esprit™ 膝下（BTK）系統的 FDA 批准，這是一項對患有周圍動脈疾病的人們具有突破性意義的創新 [1]。6 月，雅培獲得了兩款新的非處方連續葡萄糖監測系統 Lingo™和 Libre Rio™的 FDA 許可，並獲得了 AVEIR®雙腔（DR）無導聯起搏器系統的 CE 標誌 [1]。</p>
</div><p>Abbott's R&amp;D pipeline has also contributed to the company's growth, with 10 new growth opportunities announced during the first half of 2024 [1]. These opportunities include new product approvals and new treatment indications, further solidifying Abbott's position as a leader in the healthcare industry.</p>
<div class="lb-trans"><p>雅培的研發管線也為公司的增長做出了貢獻，在 2024 年上半年宣佈了 10 個新的增長機會 [1]。這些機會包括新產品批准和新的治療適應症，進一步鞏固了雅培在醫療保健行業的領先地位。</p>
</div><p>References:</p>
<p>[1] Abbott Reports Second-Quarter 2024 Results and Raises Full-Year Guidance. (2024, July 18). Retrieved from https://abbott.mediaroom.com/2024-07-18-Abbott-Reports-Second-Quarter-2024-Results-and-Raises-Full-Year-Guidance</p>
<div class="lb-trans"><p>參考資料：</p>
<p>[1] 雅培報告 2024 年第二季度業績並提高全年指引。 (2024, 7 月 18 日). 檢索自 https://abbott.mediaroom.com/2024-07-18-Abbott-Reports-Second-Quarter-2024-Results-and-Raises-Full-Year-Guidance</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://lh-prod-oper-pub-opercenter.s3.amazonaws.com/discovery-image/compress-193039c16e8bc001.png" alt="" original-src="https://lh-prod-oper-pub-opercenter.s3.amazonaws.com/discovery-image/compress-193039c16e8bc001.png"/></p>

儘管診斷收入下降，雅培的股票在第二季度穩健的業績公佈後下跌